NCOA3-specific inhibitors, such as bufalin and gossypol, block NCOA3 function, thereby negatively affecting the function of the NCOA3-p300-NF-κB complex and consequently decreasing the expression of BCL2, BCL2A1, BCL2L2, and MCL1. Downregulation of these antiapoptotic genes then promotes apoptosis and inhibits breast cancer cell growth (Fig. 8B). Here, BCL2 is linked to breast carcinoma.